Atrium Therapeutics, Inc. (RNA) Stock Ticker
RNA right now
Market factors today
Unlock the full RNA picture
About Atrium Therapeutics, Inc.
Atrium Therapeutics, Inc. is a biopharmaceutical company dedicated to revolutionizing the treatment of cardiomyopathies by delivering innovative ribonucleic acid (RNA) therapeutics directly to the heart. Their development-stage portfolio currently includes ATR 1072, a siRNA-based therapy targeting the PRKAG2 gene for the treatment of PRKAG2 syndrome, and ATR 1086, another siRNA therapy aimed at the PLN gene to address PLN cardiomyopathy. The company is also actively developing a wider range of pipeline candidates designed to combat various genetic and cardiac diseases. Founded in 2025, Atrium Therapeutics is based in San Diego, California.
RNA stock facts
| Ticker symbol | RNA |
| Exchange | NASDAQ Global Select |
| Sector | Healthcare |
| Industry | Biotechnology |
| Market cap | $141.8M |
| CEO | Kathleen Gallagher |
| Employees | 511 |
| Headquarters | San Diego, CA, US |
| IPO date | 2026-02-27 |
| Website | www.atriumtherapeutics.com |
What you can see for RNA on Tickr
Live RNA price chart with overlays, the options chain, implied move, IV rank, options flow and Strategy Lab, financial statements and consensus estimates, analyst ratings, catalysts, news with AI scoring, and an AI chat that has read the RNA report.
Rankings
FAQ
What is the ticker symbol for Atrium Therapeutics, Inc.?
The ticker symbol for Atrium Therapeutics, Inc. is RNA, listed on the NASDAQ Global Select.
What is RNA?
Atrium Therapeutics, Inc. is a biopharmaceutical company dedicated to revolutionizing the treatment of cardiomyopathies by delivering innovative ribonucleic acid (RNA) therapeutics directly to the heart. Their development-stage portfolio currently includes ATR 1072, a siRNA-based therapy targeting the PRKAG2 gene for the treatment of PRKAG2 syndrome, and ATR 1086, another siRNA therapy aimed at…